metabolic research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-26. Anything still debated is marked as such rather than presented as settled.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Following the end of the Chadian-Libyan conflict, relations with Libya were normalised in 1994. Starting in the mid-1990s, the AAT started to grow slowly but steadily. In 1995, two second-hand Aérospatiale Alouette IIIs were bought from the Netherlands. Two Mil Mi-24Ds and one Mil Mi-17 were also purchased in the late 1990s. Libya donated two Antonov An-26s in the same period, and two SIAI-Marchetti SF.260s in 2006. Two Mi-24Vs were delivered from Ukraine in 2000, as well as four Mi-17s in 2001 and 2006. Four more Mi-24Vs were delivered from the same source in 2007–2008. The expansion of the AAT in this period was fuelled by royalties from oil exports that started in the mid-2000s. In 2005, one of the two PC-7s donated by France in the 1980s was overhauled by the company Griffon Aerospace, which also bought another on the civilian market in the United States. The same company then purchased a single Pilatus PC-9 directly from Swiss manufacturer Pilatus Aircraft, and contracted around 50 French, Algerian and Mexican personnel to serve in the AAT. Griffon Aerospace then proceeded to modify one Mi-17V-5, three Mi-24Vs and the PC-9 with hardpoints allowing them to carry Mark 81 and Mark 82 bombs, sourced from Pakistan. The three Mi-24Vs were also made compatible with night-vision goggles. The weaponisation of the PC-9 caused a scandal in Switzerland, as the Chadian government had promised it would not be used in a combat role. This affair marked the end of Griffon Aerospace's work in Chad, and all of its employees left the country by March 2008.
== Side effects == Bone marrow suppression (anemia, neutropenia, thrombocytopenia) is the most commonly occurring side effect of chlorambucil. Withdrawn from the drug, this side effect is typically reversible. Like many alkylating agents, chlorambucil has been associated with the development of other forms of cancer. Less commonly occurring side effects include:
1 code 5' UTR 2 code activation peptide 2–4 code β-sandwich 4–12 code catalytic domain 12–13 code β-barrel 1 13–15 code β-barrel 2 B subunit gene is F13B. It is on chromosome 1 at the position 1q31–32.1. It spans 28 kbp, has 11 introns and 12 exons. Its mRNA is 2.2 kbp. Exon 1 codes 5' UTR. Exons 2–12 code the 10 different sushi domains.
Sources: en.wikipedia.org
== Symptoms and signs == Abdominal obesity, often assessed using the waist-to-hip ratio, is associated with hyperinsulinemia. Direct measurement of serum insulin levels can identify elevated insulin, which may precede the onset of impaired glucose tolerance or hyperglycemia by 10 to 20 years. Consequently, normal fasting blood glucose levels alone do not rule out early-stage hyperinsulinemia. Some patients may experience a variety of symptoms when hypoglycemia is present, including:
One study has found that these steroid-carrier complexes are bound by megalin, a membrane receptor, and are then taken into cells via endocytosis. One possible pathway is that once inside the cell these complexes are taken to the lysosome, where the carrier protein is degraded and the steroid hormone is released into the cytoplasm of the target cell. The hormone then follows a genomic pathway of action. This process is shown in Figure 2 to the right. The role of endocytosis in steroid hormone transport is not well understood and is under further investigation. In order for steroid hormones to cross the lipid bilayer of cells, they must overcome energetic barriers that would prevent their entering or exiting the membrane. Gibbs free energy is an important concept here. These hormones, which are all derived from cholesterol, have hydrophilic functional groups at either end and hydrophobic carbon backbones. When steroid hormones are entering membranes free energy barriers exist when the functional groups are entering the hydrophobic interior of membrane, but it is energetically favorable for the hydrophobic core of these hormones to enter lipid bilayers. These energy barriers and wells are reversed for hormones exiting membranes. Steroid hormones easily enter and exit the membrane at physiologic conditions. They have been shown experimentally to cross membranes near a rate of 20 μm/s, depending on the hormone. Though it is energetically more favorable for hormones to be in the membrane than in the ECF or ICF, they do in fact leave the membrane once they have entered it.
==== A typical assay ==== Materials: A fluorometer equipped with temperature control or similar instrumentation (qPCR machines); suitable fluorescent dye; a suitable assay plate, such as a 96-well qPCR plate. Compound solutions: Test ligands are prepared at a 50- to 100-fold concentrated solution, generally in the 10–100 mM range. For titration, a typical experimental protocol employs a set of 12 wells, comprising 11 different concentrations of a test compound with a single negative control well. Protein solution: Typically, target protein is diluted from a concentrated stock to a working concentration of ~0.5–5 μM protein with dye into a suitable assay buffer. The exact concentrations of protein and dye are defined by experimental assay development studies. Centrifugation and oil dispense: Brief centrifugation (~1000 × g, 1 min) of the assay plate to mix compounds into the protein solution, 1–2 μL of silicone oil to prevent the evaporation during heating is overlaid onto the solution (some systems use plastic seals instead), followed by an additional centrifugation step (~1000 × g, 1 min). Instrumental set up: A typical temperature ramp rates range from 0.1 to 10 °C/min but generally in the range of 1 °C/min. The fluorescence in each well is measured at regular intervals, 0.2–1 °C/image, over a temperature range spanning the typical protein unfolding temperatures of 25–95 °C.
electric sector without an initial drift length followed by a 60° magnetic sector with the same direction of curvature. Sometimes called a "Bainbridge mass spectrometer," this configuration is often used to determine isotopic masses. A beam of positive particles is produced from the isotope under study. The beam is subject to the combined action of perpendicular electric and magnetic fields. Since the forces due to these two fields are equal and opposite when the particles have a velocity given by
Sources: en.wikipedia.org
Neanderthals collected non-functional, uniquely-shaped objects, namely shells, fossils, and gems. It is unclear if these objects were simply picked up for their aesthetic qualities, or if some symbolic significance was applied to them. Some shells may have been painted. Gibraltarian palaeoanthropologists Clive and Geraldine Finlayson suggested that Neanderthals used various bird parts as artistic media, especially black feathers. A 2020 study found evidence of a 3-ply cord fragment made from conifer inner-bark fibres at Abri du Maras, France, which can be used to knit light items, such as strings for hanging beads. 115,000-year-old perforated shell beads from Cueva Antón were possibly strung together to make a necklace. There are several instances of nondescript engravings and scratches on flints, bones, pebbles, and stone slabs — as of 2014, 63 purported engravings have been reported from 27 different European and Middle Eastern Lower-to-Middle Palaeolithic sites. It is debated if these were made with symbolic intent. Neanderthals may have produced finger flutings on the walls of La Roche-Cotard over 57,000 years ago. Neanderthals used ochre, a clay earth pigment. It is unclear if this constitutes evidence of artmaking because, while modern humans have used red ochre for decorative or symbolic colouration, they have also used ochre as medicine, hide tanning agent, food preservative, and insect repellent.
== Notes == ^α Three countries - Mauritius, Saint Lucia, and Saudi Arabia - have not had figures reported by the FAO since the 1990s but are still included in the data; all three continue to produce coffee at a small scale. They are counted here as producing nations but not included in the global totals. ^β Values for China are estimated by the ICO.
The Rhizoplaca melanophthalma complex (rock-posy lichens) illustrates this complexity. Formerly treated as one circumpolar species with variable forms, the group is now recognized as several genetically distinct but partly hybridising species. Keuler and colleagues (2020) used genome-scale data and detected at least three historic hybridisation events. Network analysis showed that one lineage, Rhizoplaca shushanii, arose from hybridisation between R. melanophthalma and R. parilis and that low-level gene flow still occurs among some lineages. The hybrids lineages have unusual traits: R. shushanii is an alpine endemic with a distinct appearance, and two other lineages that were involved in introgression (gene flow between species) (R. haydenii and R. arbuscula) are vagrant forms that do not attach to rock but blow around on soil and reproduce only asexually. The study found discordance between nuclear and mitochondrial DNA trees (mitochondria from one species had introgressed into another), and the authors suggest that hybridization events might be linked to the loss of sexual reproduction and the evolution of these unusual, unattached growth forms. Systematically, the case shows that species boundaries can be porous and that reticulate evolution must be tested—single-locus barcodes can mislead when hybridisation is present. It also shows why relying on a single genetic locus (such as the ITS barcode alone) can be misleading: different genes in the same organisms have different histories if hybrids are involved.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.